Evidence map›Paper›PMID 34540055›Full record

ArticleAmerican journal of translational research2021

Expression of miR-192-5p in colon cancer serum and its relationship with clinicopathologic features.

Xu Chen, Xiandu Su, Mingli Lin, Buyuan Fu, Cong Zhou, Chen Ling, Zhongping Qian, Yanping Yao

Abstract read
In one paragraph

Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xu ChenCenter of Clinical Laboratory, First Affiliated Hospital of Soochow University Suzhou 215006, People's Republic of China.
Xiandu SuDepartment of Clinical Laboratory, People's Hospital of Danzhou Danzhou 571700, People's Republic of China.
Mingli LinDepartment of Clinical Laboratory, People's Hospital of Danzhou Danzhou 571700, People's Republic of China.
Buyuan FuDepartment of Clinical Laboratory, People's Hospital of Danzhou Danzhou 571700, People's Republic of China.
Cong ZhouDepartment of Surgical Oncology, People's Hospital of Danzhou Danzhou 571700, People's Republic of China.
Chen LingCenter of Clinical Laboratory, First Affiliated Hospital of Soochow University Suzhou 215006, People's Republic of China.
Zhongping QianCenter of Clinical Laboratory, First Affiliated Hospital of Soochow University Suzhou 215006, People's Republic of China.
Yanping YaoDepartment of Pharmacy, Suzhou Xiangcheng People's Hospital Suzhou 215006, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colon cancer has a poor prognosis due to a lack of biomarkers for early diagnosis and prognosis. The present study analyzed serum miR-192-5p expression levels in colon cancer patients and their correlations with clinicopathologic features. Relative mRNA expression was assessed by real-time fluorescence-based quantitative PCR in the serum of 164 colon cancer patients and 60 healthy controls. Patients were enrolled in a high or low miR-192-5p group according to the cutoff value determined by ROC curve analysis. The Kaplan-Meier method and univariate and multivariate Cox regression models were applied to analyze the risk factors influencing the postoperative survival of colon cancer patients. miR-192-5p mRNA expression in the colon cancer group was significantly reduced compared with the control group (P<0.01). Low miR-192-5p expression was significantly associated with a poor differentiation degree, lymphatic metastasis, vascular invasion, and high TNM stage (P=0.027, 0.001, 0.010, and <0.001, respectively). Colon cancer patients in the low miR-192-5p group exhibited a low survival rate (P<0.001). The independent risk factors for postoperative survival included lymphatic metastasis, a high TNM stage, and miR-192-5p<1.16 (P=0.017, 0.025, and 0.008, respectively). miR-192-5p may represent a promising biomarker for early diagnosis and prognosis in colon cancer patients.

Indexed as

biomarkerColon cancerdiagnosismiR-192-5pprognosis

Identifiers

PMID34540055
PMCPMC8430106

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.